[Featured Stock] Nexten Bio, Novo Nordisk Diabetes and Obesity Treatment Market Expected to Reach 44 Trillion KRW... Collaboration Highlighted↑

NexenBio is showing strong performance. This is interpreted as being influenced by the forecast that the sales of diabetes and obesity drugs from the global pharmaceutical company Novo Nordisk will reach 44 trillion KRW by 2028.

As of 11:31 AM on the 25th, NexenBio is trading at 8,310 KRW, up 4.27% compared to the previous day.

According to an analysis by the Korea Bio Association's Bio Economy Research Center of Evaluate's "Top 10 Global Specialty Pharmaceutical Companies and Top 10 Drug Sales Forecast for 2028," the combined sales of Novo Nordisk’s type 2 diabetes treatment drugs 'Ozempic' and oral diabetes drug 'Rybelsus,' and obesity treatment drug 'Wegovy' are expected to reach 33 billion USD (approximately 44 trillion KRW) by 2028.

This figure surpasses that of the immune-oncology drug 'Keytruda,' which is forecasted to be the world's top pharmaceutical sales product in 2028. Keytruda's sales last year were 20.9 billion USD (approximately 26 trillion KRW).

Currently, Wegovy (active ingredient semaglutide) is gaining worldwide popularity, leading to supply shortages. In the second quarter of this year, Wegovy sales recorded about 735 million USD (approximately 986.223 billion KRW), reportedly a sixfold increase compared to the same period last year.

Wegovy is a GLP-1 RA class drug and is one of six drugs approved by the U.S. Food and Drug Administration (FDA) for long-term obesity treatment. It is known to cross the blood-brain barrier, enhancing its weight loss efficacy.

Meanwhile, NexenBio announced that its subsidiary, RossBivo Therapeutics, has signed a Confidential Disclosure Agreement (CDA) with Novo Nordisk for the joint development and technology export of diabetes treatments.

This content was produced with the assistance of AI translation services.